Immunome (IMNM) Net Income towards Common Stockholders (2019 - 2026)

Immunome (IMNM) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$244.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 443.98% year-over-year to -$244.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$489.3 million (down 48.04% YoY) and the FY2025 annual result came in at -$404.8 million, up 1.88% from the prior year.
• Net Income towards Common Stockholders slipped to -$244.2 million in Q1 2026, from -$72.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$4.3 million in Q3 2023 to a low of -$244.2 million in Q1 2026.
• A 5-year average of -$65.3 million and a median of -$70.3 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders tumbled 2796.5% — and 2025, when it surged 66.09%.
• Tracing IMNM's Net Income towards Common Stockholders over 5 years: stood at -$7.8 million in 2022, then slumped by 1089.75% to -$92.6 million in 2023, then increased by 10.11% to -$83.3 million in 2024, then rose by 12.49% to -$72.9 million in 2025, then tumbled by 235.2% to -$244.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$244.2 million (Q1 2026), -$72.9 million (Q4 2025), and -$101.9 million (Q3 2025), per Business Quant data.